Cargando…
PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness
PAK1 confers resistance to the estrogen antagonist tamoxifen in breast cancer. However, a role for PAK1 remains to be elucidated for chemoresistance and prognosis in non-small cell lung cancer (NSCLC). We provide evidence that PAK1 confers cisplatin resistance by increasing β-catenin expression thro...
Autores principales: | Chen, Ming-Jenn, Wu, De-Wei, Wang, Yao-Chen, Chen, Chi-Yi, Lee, Huei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054675/ https://www.ncbi.nlm.nih.gov/pubmed/27713506 http://dx.doi.org/10.1038/srep34933 |
Ejemplares similares
-
Corrigendum: PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness
por: Chen, Ming-Jenn, et al.
Publicado: (2016) -
Author Correction: PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness
por: Chen, Ming-Jenn, et al.
Publicado: (2020) -
Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2
por: Tung, Min-Che, et al.
Publicado: (2015) -
miR‑122/SENP1 axis confers stemness and chemoresistance to liver cancer through Wnt/β‑catenin signaling
por: Dai, Jianbo, et al.
Publicado: (2023) -
MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2
por: Chen, Ming-Jenn, et al.
Publicado: (2018)